Small molecule therapeutics for the treatment of Alzheimer's disease through inhibition of PDE5
- Summary
- Current therapeutics for Alzheimer's disease have limited efficacy and address the symptoms instead of altering the course of the disease. This technology presents new small molecule compounds that improve memory at nanomolar concentrations and are therefore strong therapeutic candidates for Alzheimer's disease.
- Technology Benefits
- Selective treatment for Alzheimer's disease and erectile dysfunctionSmall molecules are easily transported across the blood brain barrier, making them a useful PDE5 inhibitor within the brainCan inhibit PDE5 at nanomolar concentrationsPatent Information:Patent Pending (WO/2013/109738)Tech Ventures Reference: IR CU12089
- Technology Application
- Therapeutic for the treatment of Alzheimer's diseaseDesign scaffold for the development of molecules to treat other neurological diseases and dementias for which inhibition of PDE5 may ameliorate cognitive defects -- e.g. Parkinson's and Huntington's disease
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Ron KatzColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU12089
- *Principal Investigator
-
- *Publications
- Fiorito, J., Saeed, F., Zhang, H., Staniszewski, A., Feng, Y., Francis, Y., Rao, S., Thakkar, D., Deng, S., Landry, D., Arancio, O. "Synthesis of quinoline derivatives: Discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease" European Journal of Medicinal Chemistry. 2013 Feb;60:285-294.
- Country/Region
- USA
For more information, please click Here
